Table 111Summary study characteristics for antipsychotic augmentation

Augmentation with an antipsychotic
No. trials (Total participants)10 RCTs (2554)
Study IDs
  1. THASE2007 study 1
  2. THASE2007 study 2
N/% female
  1. 362/70
  2. 483/73
  3. 55/57
  4. 274/72
  5. 381/67
  6. 58/64
  7. 28/unclear
  8. 50/50
  9. 404/63
  10. 459/68
Mean age
1.

45

2.

46

3.

45

4.

46

5–6.

44

7.

42

8–10.

44

Augmenting agent
1.

Aripiprazole

2.

Olanzapine

3–4.

Risperidone

5.

Aripiprazole

6.

Quetiapine

7.

Olanzapine

8.

Risperidone

9–10.

Olanzapine

Antidepressant
1.

SSRIs or venlafaxine

2.

Fluoxetine

3.

Range

4.

Range of ADs

5–6.

SSRI or venlafaxine

7.

Fluoxetine

8.

Venlafaxine

9–10.

Fluoxetine

Setting
1.

Outpatients

2.

Unclear

3.

Outpatients

4.

Mixed including primary care

5.

Unclear

6.

Primary care and outpatients

7.

Outpatients

8.

Mixed

9–10.

Unclear

Length of treatment
1.

6 weeks

2.

12 weeks

3.

4 weeks

4–5.

6 weeks

6–7.

8 weeks

8.

6 weeks

9–10.

8 weeks

From: 12, THE PHARMACOLOGICAL AND PHYSICAL MANAGEMENT OF DEPRESSION THAT HAS NOT ADEQUATELY RESPONDED TO TREATMENT, AND RELAPSE PREVENTION

Cover of Depression
Depression: The Treatment and Management of Depression in Adults (Updated Edition).
NICE Clinical Guidelines, No. 90.
National Collaborating Centre for Mental Health (UK).
Leicester (UK): British Psychological Society; 2010.
Copyright © The British Psychological Society & The Royal College of Psychiatrists, 2010.

All rights reserved. No part of this book may be reprinted or reproduced or utilised in any form or by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying and recording, or in any information storage or retrieval system, without permission in writing from the publishers. Enquiries in this regard should be directed to the British Psychological Society.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.